These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20084384)

  • 41. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
    Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
    Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
    Go H; Kang MJ; Kim PJ; Lee JL; Park JY; Park JM; Ro JY; Cho YM
    Pathol Oncol Res; 2019 Jan; 25(1):51-58. PubMed ID: 28963640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel tyrosine kinase inhibitors for renal cell carcinoma.
    Dorff TB; Pal SK; Quinn DI
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Systemic therapy for metastatic renal cell carcinoma].
    Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
    Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
    Yaman S; Bilgin B; Şendur MA; Hızal M; Akıncı MB; Yalçın B
    Future Oncol; 2019 Mar; 15(9):925-927. PubMed ID: 30854890
    [No Abstract]   [Full Text] [Related]  

  • 46. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas.
    Ito K
    Int J Urol; 2019 Sep; 26(9):868-877. PubMed ID: 31183903
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
    Ornstein MC; Rini BI
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
    Neill MG; Wei AC; Jewett MA
    Urology; 2007 Jul; 70(1):178.e9-11. PubMed ID: 17656238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
    Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Nishikawa T; Nakano M; Tanabe K
    Jpn J Clin Oncol; 2010 Dec; 40(12):1173-9. PubMed ID: 20696817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Molecular basis of targeted therapy in metastatic renal cancer].
    Moch H
    Pathologe; 2008 Nov; 29 Suppl 2():184-6. PubMed ID: 18751979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
    Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
    Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
    Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New insights into molecular mechanisms of sunitinib-associated side effects.
    Aparicio-Gallego G; Blanco M; Figueroa A; García-Campelo R; Valladares-Ayerbes M; Grande-Pulido E; Antón-Aparicio L
    Mol Cancer Ther; 2011 Dec; 10(12):2215-23. PubMed ID: 22161785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas.
    Hahn AW; Agarwal N
    Cancer Treat Res Commun; 2020; 24():100190. PubMed ID: 32679555
    [No Abstract]   [Full Text] [Related]  

  • 55. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
    Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
    Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of non-clear cell renal cell carcinoma: Current approaches.
    Tsimafeyeu I
    Urol Oncol; 2017 Jan; 35(1):5-13. PubMed ID: 27544302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.
    Nagao K; Shinohara N; Smit F; de Weijert M; Jannink S; Owada Y; Mulders P; Oosterwijk E; Matsuyama H
    BMC Cancer; 2018 Nov; 18(1):1114. PubMed ID: 30442117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Metastatic renal cell carcinoma, back to the future].
    Martins F; Berthold D
    Rev Med Suisse; 2016 May; 12(519):994-8. PubMed ID: 27424427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
    Biró K; Küronya Z
    Magy Onkol; 2010 Dec; 54(4):369-76. PubMed ID: 21163768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.